Edition:
United States

Shire PLC (SHP.L)

SHP.L on London Stock Exchange

5,115.00GBp
8:14am EDT
Change (% chg)

-93.00p (-1.79%)
Prev Close
5,208.00p
Open
5,185.00p
Day's High
5,197.00p
Day's Low
5,105.00p
Volume
697,391
Avg. Vol
2,784,437
52-wk High
5,377.00p
52-wk Low
2,707.19p

SHP.L

Chart for SHP.L

About

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.... (more)

Overall

Beta: 1.28
Market Cap(Mil.): £47,342.87
Shares Outstanding(Mil.): 902.03
Dividend: 3.51
Yield (%): --

Financials

  SHP.L Industry Sector
P/E (TTM): 32.43 36.61 36.60
EPS (TTM): 1.62 -- --
ROI: 3.29 14.46 13.91
ROE: 6.46 15.26 14.82

BRIEF-Shire unit prices public offering of $12.1 bln senior notes

* That its wholly owned subsidiary priced its inaugural public offering of $12.1 bln aggregate principal amount of senior notes Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Sep 20 2016

BRIEF-Shire priced its public offering of $12.1 bln aggregate principal amount of senior notes

* Priced its inaugural public offering of $12.1 billion aggregate principal amount of senior notes

Sep 19 2016

BRIEF-Shire District Court issues ruling in Hatch Waxman case regarding Shire's Lialda

* Court ruled that Cadilla Healthcare Ltd./Zydus Pharmaceuticals (USA) Inc.'s proposed generic version of Lialda does not infringe U.S. patent no. 6,773,720

Sep 16 2016

Shire's treatment for primary immunodeficiency wins FDA approval

Shire Plc said the United States Food and Drug Administration (FDA) approved its treatment for patients with primary immunodeficiency, a group of genetic disorders in which part of the body's immune system is missing or functions improperly.

Sep 14 2016

Shire's treatment for primary immunodeficiency wins FDA approval

Sept 14 Shire Plc said the United States Food and Drug Administration (FDA) approved its treatment for patients with primary immunodeficiency, a group of genetic disorders in which part of the body's immune system is missing or functions improperly.

Sep 14 2016

BRIEF-Shire's Cuvitru gets FDA nod to treat primary immunodeficiency

* Shire announces U.S. FDA approval of cuvitrutm [immune globulin subcutaneous (human), 20% solution] treatment for primary immunodeficiency

Sep 14 2016

BRIEF-Shire launches Von Willebrand disease drug in the U.S

* Announced U.S. launch of Vonvendi [von willebrand factor (recombinant)], only recombinant treatment for adults living with Von Willebrand Disease Source text for Eikon: Further company coverage:

Aug 09 2016

Elliott Associates sues AbbVie over failed bid for Shire

Aug 5 AbbVie Inc said hedge fund Elliott Associates LP has sued the pharmaceuticals company alleging that it had made misrepresentations and omissions related to a failed attempt to buy Dublin-based Shire Plc .

Aug 05 2016

UPDATE 2-Shire lifts earnings and Baxalta cost saving targets

* Shares up 3 pct (Adds further CEO quotes on cost savings, pipeline)

Aug 02 2016

Shire lifts earnings and Baxalta cost saving targets

LONDON Drugmaker Shire upgraded its profit guidance for 2016 on Tuesday, after it hiked the predicted cost saving target for its $32 billion acquisition of rare disease drugs specialist Baxalta and beat forecasts for the second quarter.

Aug 02 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00
Provider : Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.